Nanomedical Diagnostics collaborates with world-renowned research and manufacturing institutions to develop Field Effect Biosensing (FEB) technology into applications for life science research, drug discovery, and portable diagnostic and health monitoring.


The CDC is evaluating FEB technology for disease diagnostic systems.

Mayo Clinic is evaluating the diagnostic capabilities of FEB technology.

Stanford utilizes Agile R100 to gather in vitro kinetic binding data for peer-reviewed publications, including Nature.

The Scripps Research Institute uses Agile R100 in their drug discovery program.

Nanomed is partnering with Hamilton Robotics to ensure Agile R200 integrates seamlessly with Hamilton products.

Abilita is using Agile R100 to characterize mutated GPCRs.

Base Pair Biotechnologies is using Agile R100 functionalized with aptamers to detect small molecules for pharmacokinetic studies.

KGI is using FEB technology to develop point-of-care applications with no sample processing for genetic diseases.

Johns Hopkins is evaluating FEB technology to use in hand-held drug detection devices.

RGM is a co-developer of the only commercial graphene biosensor fabrication process in the world.

Samtec is our packager of large-scale quantities of graphene biosensor chips.

Nanomedical Diagnostics was one of nine companies accepted out of 104 applicants for this top San Diego start-up incubator.